Clinical Trials Logo

Melanoma (Skin) clinical trials

View clinical trials related to Melanoma (Skin).

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05990634 Active, not recruiting - Melanoma (Skin) Clinical Trials

LifeChamps Feasibility Study

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to collect data from various sources (PROM / PREM, sensors, journal data) to train AI based models in the LifeChamps digital platform in a pre-pilot, as well as partly implement a pilot/feasibility study to examine the applicability of the digital technology developed in LifeChamps, as well as the usability for patients (cancer survivors) and health care professionals

NCT ID: NCT05986331 Active, not recruiting - Melanoma (Skin) Clinical Trials

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

Start date: July 18, 2022
Phase: Phase 3
Study type: Interventional

This clinical study is designed as a randomized, double-blind trial. Subjects with unresectable, metastatic, or recurrent skin melanoma will be randomized to one of the two study groups (BCD-201 group and Keytruda group) at a 1:1 ratio. The goal of this study is to compare the efficacy and safety of BCD-201 and Keytruda as first-line therapy in subjects with unresectable, metastatic, or recurrent skin melanoma.

NCT ID: NCT05432193 Active, not recruiting - Colorectal Cancer Clinical Trials

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Start date: July 13, 2022
Phase: Phase 1
Study type: Interventional

This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.

NCT ID: NCT05421988 Active, not recruiting - Melanoma (Skin) Clinical Trials

Effectiveness of Group and Individual Training in EFT for Patients in Remission From Melanoma

Start date: October 20, 2022
Phase: N/A
Study type: Interventional

Serious medical diagnosis frequently induce fear focused on specific anticipations or generalized anxiety, along with uncertainty, insecurity, and disorientation. Other emotions such as anger, depression, hopelessness, shame, or grief may also become involved following a serious diagnosis. The adverse impact of stress on health and immune function is well-established, as well as its link to depression and anxiety. Emotional Freedom Techniques (EFT) has demonstrated efficacy in treating anxiety, depression, and PTSD. This study tests its effectiveness in reducing negative emotional symptoms in general, and fear of recurrence in particular, among individuals previously diagnosed with melanoma and currently in remission.

NCT ID: NCT04990479 Active, not recruiting - Melanoma (Skin) Clinical Trials

Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma

Start date: June 11, 2021
Phase: Phase 1
Study type: Interventional

From Protocol v3.0 dated 16Jun2022. This is an international, multicenter, open-label, multiple cohort, First in Human, phase 1b clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of a personalized vaccine (PEV) based on GAd-PEV priming and MVA-PEV boosting, combined with SoC first-line immunotherapy using an anti-PD-1 checkpoint inhibitor in patients with unresectable stage III/IV cutaneous melanoma or with stage IV NSCLC (PDL1 ≥ 50%). The PEV vaccines will be prepared on an individual basis, following a tumor biopsy performed at the time of screening and subsequent NGS analysis, to identify patient-specific tumor mutations. Both neoantigen-encoding genetic vaccines are administered intramuscularly using 1 prime with GAd-PEV and 3 boosts with MVA-PEV in combination with the licensed programmed death receptor-1 (PD-1)-blocking antibody pembrolizumab in adult patients in patients with unresectable stage III/IV cutaneous melanoma (Cohort a) or with stage IV NSCLC (PDL1 ≥ 50%) (Cohort b).

NCT ID: NCT04821570 Active, not recruiting - Breast Cancer Clinical Trials

To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment

CANINE
Start date: February 23, 2021
Phase:
Study type: Observational

This is a trial of prospective collection of serial blood samples after administration of COVID-19 vaccine in patients with cancer who are receiving active cancer treatment, planned to start therapy with 14 days of consent, or have had stem cell transplant. Cancer treatments and administration of vaccine are not controlled by the study.

NCT ID: NCT03405155 Active, not recruiting - Melanoma (Skin) Clinical Trials

Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

Start date: January 17, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab works in treating patients with stage IIB-IIC melanoma that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03291002 Active, not recruiting - Melanoma (Skin) Clinical Trials

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Start date: September 25, 2017
Phase: Phase 1
Study type: Interventional

This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.

NCT ID: NCT02993315 Active, not recruiting - Melanoma (Skin) Clinical Trials

Melanoma Patients Immunized With Natural DenDritic Cells

MIND-DC
Start date: October 2016
Phase: Phase 3
Study type: Interventional

The aim of this study is to determine whether adjuvant treatment with nDC vaccination, after complete radical lymph node dissection or sentinel node procedure in stage IIIB and IIIC melanoma patients, improves recurrence-free survival (RFS) as compared to treatment with matching placebo.

NCT ID: NCT01477463 Active, not recruiting - Melanoma, Skin Clinical Trials

Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers

Start date: September 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the signaling pathways and changes in gene expression in melanocytes of subjects with a history of non-melanoma skin cancer who are exposed to oral vitamin D. If vitamin D is found to inhibit a signaling pathway involved in the development of melanoma such as BRAF, a protein involved in cell proliferation, then oral vitamin D could be explored further as a chemoprevention for melanoma skin cancer.